TY - JOUR T1 - Beyond the Spike: identification of viral targets of the antibody responses to SARS-CoV-2 in COVID-19 patients JF - medRxiv DO - 10.1101/2020.04.30.20085670 SP - 2020.04.30.20085670 AU - Asmaa Hachim AU - Niloufar Kavian AU - Carolyn A Cohen AU - Alex WH Chin AU - Daniel KW Chu AU - Chris KP Mok AU - Owen TY Tsang AU - Yiu Cheong Yeung AU - Ranawaka APM Perera AU - Leo LM Poon AU - Malik JS Peiris AU - Sophie A Valkenburg Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/02/2020.04.30.20085670.abstract N2 - Background The SARS-CoV-2 virus emerged in December 2019 and caused a pandemic associated with a spectrum of COVID-19 disease ranging from asymptomatic to lethal infection. Serology testing is important for diagnosis of infection, determining infection attack rates and immunity in the population. It also informs vaccine development. Although several serology tests are in use, improving their specificity and sensitivity for early diagnosis on the one hand and for detecting past infection for population-based studies, are priorities.Methods We evaluated the anti-SARS-CoV-2 antibody profiles to 15 SARS-CoV-2 antigens by cloning and expressing 15 open reading frames (ORFs) in mammalian cells and screened antibody responses to them in COVID-19 patients using the Luciferase Immunoprecipitation System (LIPS).Results The LIPS technique allowed us to detect antibody responses in COVID-19 patients to 11 of the 15 SARS-CoV-2 antigens tested, identifying novel immunogenic targets. This technique shows that antigens ORF3b and ORF8 allow detection of antibody early in infection in a specific manner and reveals the immuno-dominance of the N antigen in COVID-19 patients.Conclusion Our report provides an unbiased characterization of antibody responses to a range of SARS-CoV-2 antigens. The combination of 3 SARS-CoV-2 antibody LIPS assays, i.e. N, ORF3b, and ORF8, is sufficient to identify all COVID-19 patients of our cohort even at early time-points of illness, whilst Spike alone fails to do so. Furthermore, our study highlights the importance of investigating new immunogens NSP1, ORF3b, ORF7a and ORF8 which may mediate immune functions other than neutralization which may be beneficial or harmful to the patient.Competing Interest StatementA Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed a patent application on the basis of the invention described in this study.Funding StatementThis study was partly supported by the Research Grants Scheme (GRF 17113718).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study is available upon request. ER -